NetworkNewsBreaks – Viking Therapeutics, Inc. (NASDAQ: VKTX) Shares Reverse from Early Rally on Positive Initial Data from VK2809 Study
Shares of Viking Therapeutics (NASDAQ: VKTX) are trading lower, pulling back from a pre-market surge of 10% after the company announced positive initial results from a proof-of-concept study of VK2809 for the treatment of GSD Ia, a rare orphan genetic disease. The data demonstrates that treatment with VK2809 led to statistically significant reductions in key metabolic markers of GSD Ia, including rapid and substantial reductions in liver triglyceride content, liver weight and liver weight as a percentage of body weight, as compared with vehicle-treated controls. "These initial proof-of-concept data showing VK2809's activity in this model of GSD Ia are very…







